Subscribe to Search results

In a meeting held by the haemophilia centre directors' annual meeting on 30 September 1980 Dr Craske stated that the use of small pooled concentrates would help reduce the risk of hepatitis in the haemophilic population

Published on:

A symposium was held, organised by Dr Forbes and the Royal College of Physicians and surgeons of Glasgow, which investigated liver disease in Haemophilia.

Published on:

In a meeting held by the haemophilia centre directors' annual meeting on 30 September 1980 discussed the risk of hepatitis in factor concentrates.

Published on:

In a medical study conducted in 1981, Professor Thomas explained that future problems like liver cirrhosis were likely to arise as a result of hepatis.

Published on:

Dr Winter described how the 1978 Sheffield study showed NANBH to be a really serious evolving clinical problem.

Published on:

AIDS was first mentioned in the meetings of haemophilia centre directors in autumn 1982 when it was raised, almost as an afterthought, by Professor Bloom

Published on:

The 1981 annual returns were discussed at the meeting of haemophilia directors in autumn 1982.

Published on:

Estimated requirements for factor VIII was discussed at the meeting of haemophilia directors in autumn 1982

Published on:

Professor Bloom wondered what the value of giving the hepatitis B vaccine was when non-A, non-B seemed to be a bigger problem

Published on:

Dr Craske said he would find out more about AIDS following reports in the US and the possible relationship with blood products

Published on:

A summary of all the Annual Returns for UK Haemophilia Centres for the year 1981 were produced.

Published on:

The average amount of factor IX concentrate used per haemophilia B patient increased to 26,769 units at thr UK Haemophilia Centres.

Published on:

Dr Craske circulated a prospective study protocol. Any haemophilia centre directors could use the protocol when evaluating any new concentrate products; directors would be invited to report the results in a standardised way to the UKHCDs Hepatitis Working Party and to retain serial samples of each patient's serum so a collection would be available to evaluate any new marker tests for NANBH.

Published on:

The UKHCDs Hepatitis Working Party agreed that, as AIDS had similarities in its epidemiology to Hepatitis B, enquiries would be made by members of the Working Party to ascertain the likelihood of transmission by blood or blood products and a further meeting would be held when more information was available.

Published on:

Dr Rizza wrote that AIDS had caused a stir in the haemophilia world and one very senior physician had withdrawn his factor VIII concentrates from the accident room and insisted on vetting the patients himself before any dose was given. Dr Rizza felt that AIDS "should be looked at urgently if only to clear the air and dispel some of the apprehension that has been stirred up".

Published on:

Dr Craske sent a copy of his paper about AIDS to Dr Rizza and to Dr Ludlam

Published on:

Dr Craske thought it necessary to have a meeting of the Hepatitis Working Party "to decide what further investigations need to be undertaken in the British haemophiliac population".

Published on:

Dr Craske wrote to Dr Ludlam, enclosing a copy of the paper he prepared for the MRC Hepatitis Vaccine Working Group meeting, "which describes the most recent information available about [AIDS]".

Published on:

Dr Craske wrote to Dr Lane, enclosing a copy of the paper he prepared for the MRC Hepatitis Vaccine Working Group meeting, "which describes early information about AIDS in the U.S.A."

Published on:

Dr Dale Lawrence of the Centers for Disease Control in the United States wrote to Dr Craske about the US cases of AIDS among people with haemophilia.

Published on: